biote Résultats passés
Passé contrôle des critères 1/6
biote's earnings have been declining at an average annual rate of -57.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 13.1% per year.
Informations clés
-57.2%
Taux de croissance des bénéfices
-87.1%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | 13.1% |
| Rendement des fonds propres | n/a |
| Marge nette | 3.7% |
| Prochaine mise à jour des résultats | 12 Nov 2024 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment biote gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 187 | 7 | 92 | 0 |
| 31 Mar 24 | 187 | 8 | 89 | 0 |
| 31 Dec 23 | 185 | 3 | 89 | 0 |
| 30 Sep 23 | 184 | -3 | 84 | 0 |
| 30 Jun 23 | 181 | -10 | 80 | 0 |
| 31 Mar 23 | 173 | -8 | 154 | 0 |
| 31 Dec 22 | 165 | -1 | 146 | 0 |
| 30 Sep 22 | 158 | 3 | 145 | 0 |
| 30 Jun 22 | 152 | 11 | 142 | 0 |
| 31 Mar 22 | 145 | 24 | 60 | 0 |
| 31 Dec 21 | 139 | 33 | 56 | 0 |
| 30 Sep 21 | 133 | 37 | 47 | 0 |
| 31 Dec 20 | 117 | 29 | 40 | 0 |
| 31 Dec 19 | 110 | 21 | 43 | 0 |
Des revenus de qualité: BTMD has a large one-off loss of $11.6M impacting its last 12 months of financial results to 30th June, 2024.
Augmentation de la marge bénéficiaire: BTMD became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: BTMD's earnings have declined by 57.2% per year over the past 5 years.
Accélération de la croissance: BTMD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: BTMD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: BTMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.